A new Novartis AG drug to treat heart failure should cost 17 percent less than its list price of $4,560 per year to keep health costs in line with growth in the overall U.S. economy, according to the nonprofit ICER.
In a draft report released on Friday, the Boston-based Institute for Clinical and Economic Review set its "value-based" price for Entresto at $3,799 annually. The independent ICER evaluates clinical and cost effectiveness of new medicines.
23:35 Mexico's 'El Chapo': From Selling Candy To Selling Drugs12
15:02 U.S housing starts surge in December; jobless claims near 43-year low13
03:35 Ivan Rodriguez, Tim Raines and Jeff Bagwell prove Hall of Fame does forgive18
23:10 Tim Raines, Jeff Bagwell, Pudge Rodriguez elected to Baseball Hall of Fame18